Illumina (ILMN)
(Delayed Data from NSDQ)
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$149.76 USD
+5.62 (3.90%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $149.78 +0.02 (0.01%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Zacks News
Anika Reports Top Line Data from CINGAL Study, Shares Slump
by Zacks Equity Research
Anika Therapeutics' (ANIK) shares declined 37%, after the company reported disappointing data from its phase III Cingal 16-02 study in treating patients with osteoarthritis (OA) in the knee.
4 of the Best Efficient Stocks to Buy for Superb Returns
by Tirthankar Chakraborty
We have considered four popular ratios in order to find efficient companies that have the potential to provide impressive returns
Novo Nordisk in Deal with Kallyope for Obesity, Diabetes Drugs
by Zacks Equity Research
Novo Nordisk (NVO) enters into a research collaboration and option agreement with Kallyope, Inc. to develop novel therapies for diabetes and obesity.
Alexion (ALXN) Submits Application for ALXN1210 with FDA
by Zacks Equity Research
Alexion Pharmaceuticals, Inc. (ALXN) submits a Biologics License Application (BLA) to the FDA for approval of ALXN1210 to treat patients with paroxysmal nocturnal hemoglobinuria (PNH).
Walgreens Boots' Retail Pharmacy Strong Despite Several Woes
by Zacks Equity Research
Walgreens Boots' (WBA) consistent sales rise in the Retail Pharmacy International business is encouraging. Moreover, the company steadily gains traction from a slew of strategic deals.
BSX or BAX: Which is a Better Pick for Your Portfolio Now?
by Zacks Equity Research
After considering various parameters and fundamentals, we help you make a choice between Boston Scientific (BSX) and Baxter (BAX).
Valeant Down as FDA Refuses to Approve Duobrii For Psoriasis
by Zacks Equity Research
Valeant (VRX) suffers a setback as the FDA issues a CRL for its plaque psoriasis lotion, Duobrii.
QIAGEN (QGEN) Banks on Molecular Diagnostics, Global Growth
by Zacks Equity Research
QIAGEN's (QGEN) progress with the test menu expansion is impressive. Earlier in Q1, the company also secures the Japanese approval for QuantiFERON-TB Gold Plus as an in vitro diagnostic to detect TB.
Hologic's New Panther Fusion System Gets Health Canada Nod
by Zacks Equity Research
Hologic's (HOLX) receipt of Health Canada approval for the new Panther Fusion system and Panther Fusion assays, for respiratory virus infections, is expected to boost the top line in the near term.
Here's Why You Should Add Amedisys (AMED) to Your Portfolio
by Zacks Equity Research
Amedisys' (AMED) solid performance in the recently launched Personal Care segment buoys optimism. A favorable demographic trend and strategic acquisitions also bode well for the company.
Medtronic's Expanded IN.PACT Admiral FDA Nod to Aid APV Arm
by Zacks Equity Research
Medtronic's (MDT) receipt of FDA approval for 200mm and 250mm lengths of the IN.PACT Admiral Drug-Coated Balloon (DCB) is expected to boost the top line.
Anatomy of Success: Illumina (ILMN)
by Ryan McQueeney
If investors had followed our ranking system when it flagged innovative biotech company, they would have witnessed massive profits.
Dr. Reddy's/Mylan Get FDA Nod for First Generic of Suboxone
by Zacks Equity Research
Dr. Reddy's (RDY) and Mylan announced that the FDA approved the first generic version of Suboxone (Buprenorphine and Naloxone Sublingual Film) under-the-tongue film for the treatment of opioid addiction.
Flex Pharma Down on Workforce Reduction, Ends Phase II Study
by Zacks Equity Research
Flex Pharma (FLKS) announced that the company is ending the phase II studies for its pipeline candidate FLX-787 in two indications. The company also plans to lower its workforce by about 60%.
Roche's (RHHBY) Avastin Gets Label Expansion Approval by FDA
by Zacks Equity Research
Roche (RHHBY) announced that the FDA has approved the label expansion for its oncology drug Avastin in combination with chemotherapy, for the treatment of women with advanced ovarian cancer following initial surgical resection.
Iovance Biotherapeutics (IOVA) Jumps: Stock Rises 5.1%
by Zacks Equity Research
Iovance Biotherapeutics (IOVA) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.
CVS Health's PBM Selling Season Remains Solid, Retail Grows
by Zacks Equity Research
CVS Health (CVS) significantly advances more than halfway through its 2019 renewals. Also, strong year-over-year Retail/LTC comparisons are encouraging.
Pacific Biosciences to Gain From New Genome Sequencing Tools
by Zacks Equity Research
Pacific Biosciences' (PACB) new multiplexing kit to make genome sequencing faster and cost-effective.
Here's Why You Should Invest in Genomic Health (GHDX) Now
by Zacks Equity Research
Genomic Health (GHDX) gains ground on promising reimbursement prospects for its Oncotype DX breast cancer test and solid international scenario.
ResMed Reports Positive Results for Bilevel PAP Device Study
by Zacks Equity Research
Positive results from the Bilevel Rescue study are expected to boost the uptake of ResMed's (RMD) bilevel devices.
STERIS (STE) Benefits From Core Business Expansion, Buyouts
by Zacks Equity Research
STERIS' (STE) strong organic growth across specialty services, life sciences and applied sterilization segments raises optimism on the stock.
Amedisys (AMED) Buys Back 2.4M Shares From KKR, Stock Up
by Zacks Equity Research
Amedisys (AMED) works on its strategy to deploy capital in an accretive manner, maintaining low leverage and substantial borrowing capacity for future investment.
Medtronic's (MDT) CRHF Arm Growth Strong, Rising Costs a Woe
by Zacks Equity Research
The gradually stabilizing Cardiac Rhythm & Heart Failure (CRHF) market increases investor confidence in the Medtronic (MDT) stock.
Bristol-Myers (BMY) Reports Data from CheckMate-214 Study
by Zacks Equity Research
Bristol-Myers Squibb (BMY) announces encouraging data from the phase III CheckMate -214 study.
Boston Scientific Grows on New Products Amid Recall Issues
by Zacks Equity Research
Boston Scientific's (BSX) 2018 guidance raises optimism for the company's near-term prospects.